Asian Free Trade Deal Could Strengthen Canadian Patent Rights, PhRMA Says
This article was originally published in PharmAsia News
Executive Summary
Brand industry hopes weaknesses in Canada’s intellectual property regime, including lack of patent term restoration and a higher patent utility standard for biopharmaceutical products, could be addressed through the 11-nation talks on a Trans-Pacific Partnership agreement.
You may also be interested in...
GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway
The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.
Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma